ClinicalTrials.gg
TerminatedNCT00228176AUDITORUpdated May 20, 2016

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant

A Phase 3 interventional study of Rimonabant and Placebo (for Rimonabant) in Carotid Artery Plaque, Arteriosclerosis and Obesity, sponsored by Sanofi. Terminated at 6 sites in 6 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2016-05-20.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Company decision taken in light of demands by certain national health authorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
661
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Carotid Stenosis with a site in United States — 5 open to participants now, 12 under way, none of them phase 3. Carotid Stenosis · United States.

Enrollment
6th of 52
661 · median 71
Started
2005
with 1 other
Phase 3
6 of 83
none open now
Registered
8th of 83
by date

Among the 83 studies in Carotid Stenosis with a site in United States, this one is the 6th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2005, is one of 6 in phase 3, and was the 8th registered.

Carotid Stenosis

366 studies on the registry are indexed under Carotid Stenosis; 86 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

5 of the 83 studies in Carotid Stenosis with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Carotid Stenosis studies recruiting now, 39 (64%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Carotid Stenosis with a site in United States, or all of them as a file.
02

Study summary

Objectives:

  • Primary: To evaluate the effect of rimonabant 20-mg once daily in comparison with placebo, on the quantitative progression of atherosclerosis as assessed by carotid artery intima-media thickness (CIMT)
  • Secondary: To evaluate the safety and tolerability of the above rimonabant regimen in the study population of atherosclerosis patients.
Read the detailed description

This is a Phase III, prospective, multicentre, multinational, randomized, double-blind, placebo-controlled, 2-arm parallel group trial (rimonabant 20-mg od vs placebo). There will be a three-stage screening process including successively a Screening visit, a Screening CIMT and a validation of the Screening CIMT by the Imaging Core Laboratory. Patients complying with all inclusion and exclusion criteria will be randomized in one of the 2 treatment groups less than two weeks after Screening visit. Study drug (rimonabant 20 mg od or matching placebo) will be administered during 30 to 32 months. At inclusion, patients will be counseled to follow a mild hypocaloric diet, to increase their exercise level, and to stop smoking (if smokers). Glucose/lipid parameters will be assessed at Baseline and every 6 months until the Month 30 visit. CIMT will be performed at Baseline and every 6 months until final assessment at Month 30 (primary endpoint).A post-treatment follow-up visit at Month 35 will allow the collection of all adverse events and cardiovascular outcomes occurring after last study drug administration

03

Conditions studied

  • Carotid Artery Plaque
  • Arteriosclerosis
  • Obesity
  • Metabolic Syndrome X

Keywords

  • Metabolic syndrome
  • Carotid Atherosclerosis
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and signed
  • Age greater than or equal to 55 years
  • Abdominal obesity defined by waist circumference > 88 cm (35 inches) in women and > 102 cm (40 inches) in men
  • Metabolic syndrome diagnosed on the basis of at least two of the following additional risk factors:

    1. Triglyceride level equal to or greater than 150 mg/dL
    2. HDL cholesterol less than 40 mg/dL in men or 50 mg/dL in women
    3. Fasting glucose of equal to or greater than 110 mg/dL
    4. High blood pressure defined as equal to or greater than 140 mmHg systolic and/or equal to or greater than 90 mmHg diastolic at screening visit or current treatment by antihypertensive medication.
  • Ultrasonographic evidence at Screening quantitative B-mode ultrasound imaging of a minimal CIMT measurement of greater than or equal to 0.7 mm in either of the far walls of the common carotid artery, and maximal CIMT measurement less than 3 mm in any carotid artery segment.
  • All 6 carotid artery segments must have ultrasound images for all CIMT measurements
  • Screening CIMT recording deemed to be of acceptable CIMT image quality, and demonstrating adherence to the CIMT interrogation protocol, as determined by the Imaging Core Laboratory's assessment.

Exclusion criteria

Exclusion Criteria:

  • History of very low calorie diet or surgical procedures for weight loss within 6 months prior to screening visit
  • Obesity of known endocrine origin
  • Uncontrolled diabetes, i.e. with > 10%
  • Anticipated survival less than 27 months
  • Presence of any severe medical or psychological condition, that in the opinion of the Investigator, would compromise the subject's safety or successful participation in the study
  • Presence of any other condition (e.g. geographic, social, or other), actual or anticipated, that the Investigator feels would restrict or limit the subject's participation for the duration of the study
  • Receipt of any treatment (drug or device) within 30 days prior to Screening
  • Previous participation in a rimonabant study
  • Total occlusion of any carotid artery segment
  • Previous history of carotid intervention
  • Patient considered at high risk of carotid intervention during the next 27 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
661 participants (actual)

Study arms

  • Experimental
    Rimonabant

    Rimonabant 20 mg once daily

    Drug: Rimonabant

  • Placebo comparator
    Placebo

    Placebo (for Rimonabant) once daily.

    Drug: Placebo (for Rimonabant)

Interventions

  • Tablet, oral administration

    Also known as: SR141716, Acomplia

  • DrugPlacebo (for Rimonabant)

    Tablet, oral administration

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline in averaged per patient carotid artery intima-media thickness (CIMT)

    Time frame: Month 30

Secondary outcomes

  1. First occurrence of any component of stroke/myocardial infarction (MI)/cardiovascular death

    Time frame: From randomization to Month 35

  2. First occurrence of any component of stroke/MI/cardiovascular death/hospitalization for revascularization procedure, unstable angina, transient ischemic attack (TIA)

    Time frame: From randomization to Month 35

07

Study locations

6 sites
  • Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807, United States
  • Sanofi-Aventis Administrative Office
    Laval, Canada
  • Sanofi-Aventis Administrative Office
    Paris, France
  • Sanofi-Aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-Aventis Administrative Office
    Barcelona, Spain
  • Sanofi-Aventis Administrative Office
    Guildford Surrey, United Kingdom
08

References and documents

Publications

  • O'Leary DH, Reuwer AQ, Nissen SE, Despres JP, Deanfield JE, Brown MW, Zhou R, Zabbatino SM, Job B, Kastelein JJ, Visseren FL; AUDITOR investigators. Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart. 2011 Jul;97(14):1143-50. doi: 10.1136/hrt.2011.223446. Epub 2011 May 24. PubMed 21610270 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2005
First posted
Sep 28, 2005
Start
Aug 2005
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results delay requested
Apr 21, 2016
Last update
May 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00228176
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 28, 2005
Start date
Aug 2005
Primary completion
Apr 2009
Completion
Apr 2009
Last update
May 20, 2016

Study contacts

John JP Kastelein, MD
study chair · Amsterdam UMC, location VUmc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion